STAAR Surgical Reports First Quarter Results

Date : 05/01/2019 @ 8:01PM
Source : Business Wire
Stock : STAAR Surgical Company (STAA)
Quote : 34.74  -0.4 (-1.14%) @ 5:46PM

STAAR Surgical Reports First Quarter Results

STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more STAAR Surgical Charts.

ICL Units Up 39% Resulting in Seventh Consecutive Quarter of Significant Growth

Earnings per Share of $0.03

Announces U.S. Surgeons Summit

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the first quarter ended March 29, 2019.

First Quarter 2019 Overview

  • Net Sales of $32.6 Million Up 20% from the Prior Year Quarter
  • ICL Sales Up 31% and Units Up 39% from the Prior Year Quarter
  • ICL Sales Up 34% and Net Sales Up 23% on a Constant Currency Basis from the Prior Year Quarter
  • Gross Margin at 74.2% Up 250 Basis Points from the Prior Year Quarter
  • First Quarter Net Income of $0.03 per Share vs. Prior Year Net Income of $0.01 per Share
  • Cash, Cash Equivalents and Restricted Cash Ended the Quarter at $102.2 Million

“Our ICL family of lenses continue to grow at rates significantly above reported growth for the Ophthalmic Refractive sector,” said Caren Mason, President and CEO of STAAR Surgical. “Total ICL units grew 39% globally in the first quarter including 86% growth in Japan, 62% in Korea, 56% in China, 27% in Germany and 23% in India as compared to the prior year quarter. As we recognize and appreciate seven quarters of strong double digit ICL sales and unit growth, we anticipate the strong future our product pipeline and market expansion should provide. The U.S. is one of many markets with significant potential for the ICL and we are pleased to announce our inaugural invitation only U.S. Surgeons Summit. This summer weekend summit will bring together key ophthalmic opinion leaders and executives for educational, podium and panel participation and a thoughtful exchange of ideas as we execute our path forward in the U.S. Joining the U.S. contingent will be top surgeons from China, Japan and Germany who will share their clinical pathways, learnings, and business models to a new ICL continuum of visual freedom care and economic expansion. We are delighted to report the initial response to our surgeon outreach has been very strong with U.S. refractive surgeon opinion leaders leading educational sessions and surgeons from the largest refractive markets in the U.S. participating.”

Financial Overview – Q1 2019

Net sales were $32.6 million for the first quarter of 2019, up 20% compared to $27.1 million reported in the prior year quarter. The sales increase was driven by ICL revenue and unit growth of 31% and 39%, respectively. Other Product Sales decreased 19% compared to the prior year quarter. Currency, primarily the Euro, negatively impacted Net Sales by approximately $0.7 million in the first quarter. Adjusting for the impact of Currency, Net sales in the first quarter of 2019 were $33.3 million, representing 23% growth over the prior year quarter.

Gross profit margin for the first quarter of 2019, was 74.2% compared to the prior year period of 71.7%. The 250 basis point increase in gross profit margin for the quarter is due to favorable product mix resulting from increased sales of ICLs and decreased sales of injector parts and lower unit costs, partially offset by the effect of lower average selling prices (ASPs) for lower diopter ICLs and large volume commitment strategic partners.

Operating expenses for the quarter were $22.6 million compared to the prior year quarter of $18.6 million. General and administrative expenses were $6.8 million compared to the prior year quarter of $5.8 million. The increase in general and administrative expenses was due to increased headcount and salary-related expenses including stock-based compensation and increased facility costs. Marketing and selling expenses were $10.1 million compared to the prior year quarter of $7.5 million. The increase in marketing and selling expenses was due to increased headcount and salary-related expenses including stock-based compensation, increased travel expenses and continued investments in digital, strategic, and consumer marketing. Research and development expenses were $5.6 million compared to the prior year quarter of $5.4 million.

Net income for the first quarter of 2019 was $1.4 million or approximately $0.03 per share compared with net income of $0.6 million or $0.01 per share for the prior year quarter. Non-GAAP Adjusted Net Income for the first quarter of 2019 was $4.3 million or $0.09 per share compared to $2.0 million or $0.05 per share for the prior year quarter. The reconciliation between GAAP and non-GAAP financial information is provided in the financial tables included with this release.

Cash, cash equivalents and restricted cash at March 29, 2019 totaled $102.2 million, compared to $104.0 million at the end of the fourth quarter of 2018. The Company generated $0.7 million in cash from operations in the first quarter.

Conference Call

The Company will host a conference call and webcast today, Wednesday, May 1, 2019 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 2299537), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Conference ID 2299537) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 855-859-2056 for domestic callers and 404-537-3406 for international callers. An archived webcast will also be available at www.staar.com.

Use of Non-GAAP Financial Measures

This press release includes supplemental non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. “Adjusted Net Income” and “Adjusted Net Income Per Share” exclude the following items that are included in “Net Income” as calculated in accordance with U.S. generally accepted accounting principles (“GAAP”): gain or loss on foreign currency transactions and stock-based compensation expenses. Management believes that “Adjusted Net Income” and “Adjusted Net Income Per Share” are useful to investors in gauging the outcome of the key drivers of the business performance: the ability to increase sales revenue and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management has control.

Management has also excluded gains and losses on foreign currency transactions because of the significant fluctuations that can result from period to period as a result of market driven factors. Stock-based compensation expenses consist of expenses for stock options and restricted stock under the Financial Accounting Standards Board’s Accounting Standards Codification (ASC) 718. In calculating Adjusted Net Income and Adjusted Net Income Per Share, STAAR excludes these expenses because they are non-cash expenses and because of the complexity and considerable judgment involved in calculating their values. In addition, these expenses tend to be driven by fluctuations in the price of our stock and not by the same factors that generally affect our other business expenses.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian ICLs have been implanted to date. To learn more about the ICL go to: www.discovericl.com. STAAR markets lenses in over 75 countries and had approximately 475 full-time equivalent employees at December 28, 2018. Headquartered in Lake Forest, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia, CA. For more information, please visit the Company’s website at www.staar.com.

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, including those relating to the plans, strategies, and objectives of management for 2019 or prospects for achieving such plans, expectations for sales, revenue, or earnings, product safety or effectiveness, and any statements of assumptions underlying any of the foregoing, including those relating to our product pipeline and market expansion activities. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company’s Annual Report on Form 10-K for the year ended December 28, 2018 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events.

These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval, or to take enforcement action; potential international trade disputes; and the willingness of surgeons and patients to adopt a new or improved product and procedure. The Visian ICL with CentraFLOW, now known as EVO Visian ICL, is not yet approved for sale in the United States.

    Consolidated Balance Sheets (in 000's) Unaudited  

 

 

ASSETS

March 29,2019

December 28,2018

Current assets: Cash and cash equivalents $ 102,111 $ 103,877 Accounts receivable trade, net 26,601 25,946 Inventories, net 16,439 16,704 Prepayments, deposits, and other current assets   7,534     5,045   Total current assets   152,685     151,572   Property, plant, and equipment, net 11,300 11,451 Finance lease right-of-use assets, net 2,445 - Operating lease right-of-use assets, net 6,629 - Intangible assets, net 263 243 Goodwill 1,786 1,786 Deferred income taxes 1,275 1,278 Other assets   836     1,009   Total assets $ 177,219   $ 167,339     LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Line of credit $ 3,272 $ 3,780 Accounts payable 7,018 6,524 Obligations under finance leases 1,158 1,098 Obligations under operating leases 2,495 - Allowance for sales returns 2,971 2,895 Other current liabilities   11,317     13,431   Total current liabilities   28,231     27,728   Obligations under finance leases 656 459 Obligations under operating leases 4,270 - Deferred income taxes 1,100 1,022 Asset retirement obligations 206 206 Deferred rent - 188 Pension liability   5,418     5,310   Total liabilities   39,881     34,913       Stockholders' equity: Common stock 444 442 Additional paid-in capital 292,722 289,584 Accumulated other comprehensive loss (1,343 ) (1,320 ) Accumulated deficit   (154,485 )   (156,280 ) Total stockholders' equity   137,338     132,426   Total liabilities and stockholders' equity $ 177,219   $ 167,339                 Consolidated Statements of Income (In 000's except for per share data) Unaudited     Three Months Ended

% ofSales

March 29, 2019

% ofSales

March 30, 2018 Fav (Unfav) Amount %   Net sales 100.0 % $ 32,583 100.0 % $ 27,093 $ 5,490 20.3 %   Cost of sales 25.8 %   8,403   28.3 %   7,662     (741 ) -9.7 %   Gross profit 74.2 %   24,180   71.7 %   19,431     4,749   24.4 %   Selling, general and administrative expenses: General and administrative 21.0 % 6,837 21.3 % 5,771 (1,066 ) -18.5 % Marketing and selling 31.1 % 10,143 27.5 % 7,454 (2,689 ) -36.1 % Research and development 17.3 %   5,635   20.0 %   5,407     (228 ) -4.2 % Total selling, general, and administrative expenses 69.4 % 22,615 68.8 % 18,632 (3,983 ) -21.4 %   Operating income 4.8 %   1,565   2.9 %   799     766   95.9 %   Other income (expense): Interest Income (expense), net 0.8 % 271 0.0 % (12 ) 283 2358.3 % Loss on foreign currency transactions -0.7 % (248 ) -0.3 % (77 ) (171 ) -222.1 % Royalty income 0.5 % 171 0.6 % 157 14 8.9 % Other income, net 0.3 %   97   0.1 %   17     80   470.6 % Total other income, net 0.9 %   291   0.4 %   85     206   242.4 %   Income before provision for income taxes 5.7 % 1,856 3.3 % 884 972 110.0 %   Provision for income taxes 1.5 %   489   1.1 %   301     (188 ) -62.5 %   Net income 4.2 % $ 1,367   2.2 % $ 583   $ 784   134.5 %     Net income per share - basic $ 0.03   $ 0.01   Net income per share - diluted $ 0.03   $ 0.01     Weighted average shares outstanding - basic   44,235     41,410   Weighted average shares outstanding - diluted   46,913     43,087           Consolidated Statements of Cash Flows (in 000's) Unaudited Three Months Ended

March 29,2019

March 30,2018

Cash flows from operating activities: Net income $ 1,367 $ 583 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation of property and equipment 1,222 549 Amortization of long-lived intangibles 8 9 Deferred income taxes 79 92 Change in net pension liability 119 87 Stock-based compensation expense 2,641 1,301 Loss on disposal of property and equipment - 6 Provision for sales returns and bad debts (34 ) 514 Inventory provision 455 506 Changes in working capital: Accounts receivable (554 ) (2,755 ) Inventories (7 ) (396 ) Prepayments, deposits and other current assets (2,317 ) (730 ) Accounts payable (185 ) 2,038 Other current liabilities   (2,063 )   726   Net cash provided by operating activities   731     2,530     Cash flows from investing activities: Acquisition of property and equipment (2,203 ) (965 ) Increase in patents and licenses   (30 )   -   Net cash used in investing activities   (2,233 )   (965 )   Cash flows from financing activities: Repayment on line of credit (499 ) - Repayment of finance lease obligations (365 ) (380 )

Proceeds from vested restricted stock and exercise of stock options

  624     454   Net cash provided by (used in) financing activities   (240 )   74     Effect of exchange rate changes on cash, cash equivalents and restricted cash   (24 )   612     (Decrease) increase in cash, cash equivalents and restricted cash (1,766 ) 2,251 Cash, cash equivalents and restricted cash, at beginning of the period   103,999     18,641   Cash, cash equivalents and restricted cash, at end of the period $ 102,233   $ 20,892               Global Sales (in 000's) Unaudited     Three Months Ended

 

 

% Change Sales by Region

March 29, 2019

March 30, 2018

Fav (Unfav) North America 6.7 % $ 2,198 7.7 % $ 2,079 5.7 % Europe 21.6 % 7,027 25.8 % 6,990 0.5 % Middle East, Africa, Latin America 3.8 % 1,238 5.6 % 1,519 -18.5 % Asia Pacific 67.9 %   22,120 60.9 %   16,505 34.0 % Total Sales 100.0 % $ 32,583 100.0 % $ 27,093 20.3 %     Core Product Sales ICLs 85.3 % $ 27,786 78.1 % $ 21,158 31.3 % Other Product Sales IOLs 12.3 % 4,017 15.0 % 4,058 -1.0 % Injector Parts and Other 2.4 %   780 6.9 %   1,877 -58.4 % Total Other Sales 14.7 %   4,797 21.9 %   5,935 -19.2 % Total Sales 100.0 % $ 32,583 100.0 % $ 27,093 20.3 %       Reconciliation of Non-GAAP Financial Measure (in 000's) Unaudited Three Months Ended   March 29, 2019   March 30, 2018 Net income (as reported) $ 1,367 $ 583 Less: Foreign currency impact 248 77 Stock-based compensation expense   2,641     1,301 Net income (adjusted) $ 4,256   $ 1,961   Net income per share, basic (as reported) $ 0.03 $ 0.01 Foreign currency impact 0.01 - Stock-based compensation expense   0.06     0.03 Net income per share, basic (adjusted) $ 0.10   $ 0.05   Net income per share, diluted (as reported) $ 0.03 $ 0.01 Foreign currency impact 0.01 - Stock-based compensation expense   0.06     0.03 Net income per share, diluted (adjusted) $ 0.09   $ 0.05   Weighted average shares outstanding - Basic 44,235 41,410 Weighted average shares outstanding - Diluted 46,913 43,087   Note: Net income per share (adjusted), basic and diluted, may not add due to rounding  

Investors & MediaBrian MooreSr. Director, Investor, Media Relations and Corporate Development(626) 303-7902, Ext. 3023bmoore@staar.com

Latest STAA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.